PFD report

Kathleen Gabrielle Bamforth · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 20 Jul 2018•West Yorkshire (Western)

Report record

Published report and response evidence

This page connects the concerns raised in this report with statements found in recipients’ published responses. A link shows a clear evidence connection; it does not assign responsibility.

View original report
Concerns
2

Raised in this report

Recipients
1

Named on the report

Responses found
1

Of 1 recipient

Stated actions
0

Described in responses

Recipients and published responses

Source document

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised2

  1. Lack of routine blood screening for long-term clomipramine treatment
  2. Potentially unsafe clomipramine prescribing practices
    Part of recurring concern: Unsafe medication prescribing
Responses linked to these concerns

Each statement is shown once, even when linked to more than one concern.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.1

  1. Position

    Existing product information and NICE guidance provide monitoring and toxicity-risk controls; routine clomipramine blood-level screening is not currently recommended.

    Stated by Department of Health and Social CareExisting arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Lack of routine blood screening for long-term clomipramine treatment

Wider context from the report

“• To review current practice guidelines with respect to the prescription of clomipramine • To consider the merits of routine blood screens in patients prescribed with long term use of clomipramine. ”

Is this part of a recurring concern?

No recurring-concern membership is currently published.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Potentially unsafe clomipramine prescribing practices

Wider context from the report

“• To review current practice guidelines with respect to the prescription of clomipramine • To consider the merits of routine blood screens in patients prescribed with long term use of clomipramine. ”

Is this part of a recurring concern?

Yes — Unsafe medication prescribing.

Open source report

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Existing product information and NICE guidance provide monitoring and toxicity-risk controls; routine clomipramine blood-level screening is not currently recommended.

Verbatim wording from the response

“On the matter of clinical guidelines, NICE has advised that its guidelines set out the expectation that prescribers will use a drug's Summary of Product Characteristics (SmPC), as well as the 'British National Formulary' (BNF) to inform decisions made with individual patients.”

Source location

2018-0247-Response-by-Department-of-Health
Page 1 · response
Published 24 September 2018

Open published response

Other statements in published responses

These actions and other statements could not be clearly connected to one concern in this report.

Recipient positions A position is what a recipient says about a concern when they do not describe a specific action.1

  1. 1

    Clomipramine is not recognised to interact with the patient's prescribed pregabalin and naproxen.

    Stated by Department of Health and Social CareDisputes the concernThe respondent disagreed with part of the concern or the basis for it.

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Clomipramine is not recognised to interact with the patient's prescribed pregabalin and naproxen.

Verbatim wording from the response

“In relation to the additional prescribed medication detailed in your report, the clomipramine SmPC advises that concurrent use of clomipramine with drugs that are substrates or inhibitors of cytochrome P450 2D6 is not recommended as these drugs may increase the plasma concentration of clomipramine; opiates (such as tramadol) are included in the list of examples of such drugs provided in the SmPC. The SmPC for tramadol advises that tramadol can increase the potential for TCAs to cause convulsions, and that concomitant use of tramadol and TCAs may cause serotonin syndrome. Clomipramine is not recognised to interact with the other prescribed medication in your report (pregabalin and naproxen).”

Source location

2018-0247-Response-by-Department-of-Health
Page 3 · response
Published 24 September 2018

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
1/1

Data last updated 7 September 2026